HANNAH RAY: Open Payments
NPI 1972287415 · CONWAY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,111 in 46 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $334 · 2025 $1,111
Food & beverage: $1,111
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 10 | $349 |
| GlaxoSmithKline, LLC. | 7 | $162 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| GENZYME CORPORATION | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 3 | $59 |
| Averitas Pharma Inc. | 2 | $57 |
| Corcept Therapeutics | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Tandem Diabetes Care, Inc. | 3 | $32 |
Products named: UPTRAVI, OPSUMIT, NUCALA, DUPIXENT, GLASSIA, QUTENZA, Korlym, OFEV.
Industry payments across AR — which companies pay providers there.
